Leap Therapeutics, Inc. (LPTX) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.35
↓-79% vs avg
5yr avg: 1.71
30Y Low0.5·High5.2
ROE
↑
16.3%
↓+121% vs avg
5yr avg: -76.2%
30Y Low-267%·High16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LPTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Leap Therapeutics, Inc. trades at 11.0x earnings, 34% below its 5-year average of 16.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 51%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $82M | $108M | $85M | $51M | $278M | $133M | $25M | $29M | $57M | — |
| Enterprise Value | $51M | $68M | $61M | $14M | $30M | $164M | $70M | $24M | $13M | $32M | — |
| P/E Ratio → | 10.99 | 16.57 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 185.38 | 13.28 | 2.61 | — | — | — |
| P/B Ratio | 0.35 | 0.53 | 3.09 | 1.41 | 0.93 | 2.58 | 1.98 | 4.42 | 3.14 | 5.16 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LPTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 109.08 | 7.01 | 2.47 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
LPTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 16.3% indicates solid capital efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | 50.9% | 52.9% | — | — | — |
| Operating Margin | — | — | — | — | — | -2761.7% | -34.3% | -35.9% | — | — | — |
| Net Profit Margin | — | — | — | — | — | -2705.8% | -33.7% | -35.6% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.3% | 16.3% | -141.9% | -141.9% | -67.2% | -46.3% | -9.3% | -46.3% | -228.1% | -267.4% | — |
| ROA | 14.4% | 14.4% | -110.8% | -124.4% | -62.0% | -43.1% | -8.6% | -24.8% | -96.1% | -167.4% | -148.1% |
| ROIC | -48.3% | -48.3% | — | -545.5% | -308.3% | — | -59.5% | — | — | — | — |
| ROCE | -42.4% | -42.4% | -147.2% | -151.2% | -69.7% | -46.9% | -9.1% | -35.2% | -172.7% | -140.8% | — |
LPTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $14M exceeds total debt of $38000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -1.34 | -1.17 | -0.37 | -1.06 | -0.94 | -0.24 | -1.77 | -2.32 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1051.17 | -1010.39 | -88.36 | -151.13 | -1618.47 | -267.37 | -22.32 |
Net cash position: cash ($14M) exceeds total debt ($38000)
LPTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Leap Therapeutics, Inc.'s current ratio of 35.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.64x to 35.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 17.07 | 11.70 | 37.37 | 3.50 | 2.69 | 4.55 | 0.11 |
| Quick Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 16.62 | 11.70 | 36.83 | 3.09 | 2.69 | 4.55 | 0.11 |
| Cash Ratio | 3.08 | 3.08 | 3.36 | 5.57 | 14.03 | 11.51 | 35.44 | 1.52 | 2.52 | 4.23 | 0.02 |
| Asset Turnover | — | — | — | — | — | 0.01 | 0.14 | 1.11 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 5.03 | 7.06 | — | — | 0.83 |
| Days Sales Outstanding | — | — | — | — | — | 289.32 | 73.09 | 77.07 | — | — | — |
LPTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Leap Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 9.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.1% | 6.0% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $71M | $38M | $20M | $11M | $9M | $6M | $2M | $1M | $918858 | $939241 |
Peer Comparison
Compare LPTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LPTXYou | $65M | 11.0 | — | — | — | — | 16.3% | -48.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 ZYME | $2B | -24.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 ALLO | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See LPTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LPTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LPTX vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonLPTX — Frequently Asked Questions
Quick answers to the most common questions about buying LPTX stock.
What is Leap Therapeutics, Inc.'s P/E ratio?
Leap Therapeutics, Inc.'s current P/E ratio is 11.0x. The historical average is 16.6x.
What is Leap Therapeutics, Inc.'s ROE?
Leap Therapeutics, Inc.'s return on equity (ROE) is 16.3%. The historical average is -95.6%.
Is LPTX stock overvalued?
Based on historical data, Leap Therapeutics, Inc. is trading at a P/E of 11.0x. Compare with industry peers and growth rates for a complete picture.